fda glp-1 compounding warning october 2025 alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products Compound versions of GLP-1 drugs

The medication is indicated for adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity

Vitamin Therapy for Fatigue In a fast-paced world where energy and mental clarity are essential, low B-12 levels can quietly drain quality of life

our model assumes a 25% annual attrition rate, and that lapsed patients regain about two-thirds of the weight lost. Household impacts While survey data focuses on people taking obesity medicines, we could see a greater change to food consumption if the behavioral changes affect people in AOM patients households or social circles, speculates Morgan Stanley

Diabetes & Metabolic Syndrome , 17(7), 102798